{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T19:21:12Z","timestamp":1758050472595,"version":"3.44.0"},"reference-count":17,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["canadianjournalofophthalmology.ca","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Ophthalmology"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.jcjo.2022.03.004","type":"journal-article","created":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T07:48:43Z","timestamp":1649663323000},"page":"356-360","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Comparison of netarsudil and latanoprostene bunod as adjuncts to maximum medical therapy in primary open-angle glaucoma"],"prefix":"10.1016","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3482-0547","authenticated-orcid":false,"given":"Tyler","family":"Bahr","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Woolf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hayley","family":"Favre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4715-8801","authenticated-orcid":false,"given":"Corey","family":"Waldman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcjo.2022.03.004_bib0001","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1001\/archopht.1997.01100160749014","article-title":"Maximal medical therapy for glaucoma","volume":"115","author":"Zimmerman","year":"1997","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jcjo.2022.03.004_bib0002","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.2147\/OPTH.S154001","article-title":"Profile of netarsudil ophthalmic solution and its potential in the treatment of open-angle glaucoma: evidence to date","volume":"12","author":"Dasso","year":"2018","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jcjo.2022.03.004_bib0003","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1080\/14656566.2017.1293654","article-title":"Latanoprostene bunod ophthalmic solution 0.024% for IOP lowering in glaucoma and ocular hypertension","volume":"18","author":"Kaufman","year":"2017","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jcjo.2022.03.004_bib0004","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/IJG.0000000000000831","article-title":"Latanoprostene bunod 0.024% in subjects with open-angle glaucoma or ocular hypertension: pooled phase 3 study findings","volume":"27","author":"Weinreb","year":"2018","journal-title":"J Glaucoma"},{"key":"10.1016\/j.jcjo.2022.03.004_bib0005","article-title":"Netarsudil for the treatment of open-angle glaucoma and ocular hypertension: a literature review","author":"Gonzalez","year":"2020","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jcjo.2022.03.004_bib0006","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/j.ophtha.2009.06.022","article-title":"A clinician's guide to the assessment and management of nonadherence in glaucoma","volume":"116","author":"Budenz","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2022.03.004_bib0007","article-title":"Experience with netarsudil 0.02% and latanoprostene bunod 0.024% as adjunctive therapy for glaucoma","author":"Mehta","year":"2021","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.jcjo.2022.03.004_bib0008","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1080\/03007995.2021.1901222","article-title":"A multicenter, open-label study of netarsudil for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension in a real-world setting","volume":"37","author":"Zaman","year":"2021","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jcjo.2022.03.004_bib0009","doi-asserted-by":"crossref","first-page":"4367","DOI":"10.2147\/OPTH.S337105","article-title":"Effectiveness of netarsudil as an additional therapy for glaucoma in patients already on maximally tolerated medical therapy","volume":"15","author":"Villegas","year":"2021","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jcjo.2022.03.004_bib0010","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/eye.2017.1","article-title":"Surveillance of sight loss due to delay in ophthalmic treatment or review: frequency, cause and outcome","volume":"31","author":"Foot","year":"2017","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.jcjo.2022.03.004_bib0011","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ophtha.2016.01.019","article-title":"Latanoprostene bunod 0.024% versus timolol maleate 0.5% in subjects with open-angle glaucoma or ocular hypertension: the APOLLO study","volume":"123","author":"Weinreb","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2022.03.004_bib0012","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1136\/bjophthalmol-2014-305908","article-title":"A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study","volume":"99","author":"Weinreb","year":"2015","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jcjo.2022.03.004_bib0013","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.ajo.2016.05.012","article-title":"Comparison of latanoprostene bunod 0.024% and timolol maleate 0.5% in open-angle glaucoma or ocular hypertension: the LUNAR study","volume":"168","author":"Medeiros","year":"2016","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jcjo.2022.03.004_bib0014","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ajo.2017.11.019","article-title":"Two phase 3 clinical trials comparing the safety and efficacy of netarsudil to timolol in patients with elevated intraocular pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2)","volume":"186","author":"Serle","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jcjo.2022.03.004_bib0015","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ajo.2019.01.003","article-title":"Long-term safety and ocular hypotensive efficacy evaluation of netarsudil ophthalmic solution: Rho Kinase Elevated IOP Treatment Trial (ROCKET-2)","volume":"200","author":"Kahook","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jcjo.2022.03.004_bib0016","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ajo.2019.03.002","article-title":"Once-daily netarsudil versus twice-daily timolol in patients with elevated intraocular pressure: the randomized phase 3 ROCKET-4 study","volume":"204","author":"Khouri","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jcjo.2022.03.004_bib0017","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1177\/112067210001000201","article-title":"A pooled-data analysis of three randomized, double-masked, six-month clinical studies comparing the intraocular pressure reducing effect of latanoprost and timolol","volume":"10","author":"Hedman","year":"2000","journal-title":"Eur J Ophthalmol"}],"container-title":["Canadian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418222000941?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418222000941?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T20:10:44Z","timestamp":1757794244000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0008418222000941"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S0008418222000941"],"URL":"https:\/\/doi.org\/10.1016\/j.jcjo.2022.03.004","relation":{},"ISSN":["0008-4182"],"issn-type":[{"type":"print","value":"0008-4182"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of netarsudil and latanoprostene bunod as adjuncts to maximum medical therapy in primary open-angle glaucoma","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcjo.2022.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Canadian Ophthalmological Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}